Sr. Director/Executive Director, Program Leader
Core
Define and execute the asset strategy for CLYM116 (anti-APRIL monoclonal antibody) leading late-stage development, registration, and life-cycle management while serving as the main alliance manager with a partner company.
Role type
Senior executive program leader (biopharma)
Builds
Late-stage development and commercial launch of CLYM116
Domain
Biotechnology / Immune-mediated diseases
Required skills
Integrated global development planning, Phase 3 to approval leadership, global regulatory submission management, cross-functional matrix team leadership, alliance/partnership management, commercial strategy integration, risk management, budget oversight
Preferred skills
IgA nephropathy or glomerular disease experience, monoclonal antibody development, lean clinical-stage organization experience, board presentation experience, co-development partnership management
Technologies
None stated
Responsibilities
Develop and own the integrated global development plan and lifecycle management strategy for CLYM116; Lead cross-functional program teams across Clinical, Regulatory, CMC, Medical, Finance, and Commercial; Serve as alliance lead managing partner relationships and joint governance; Translate asset strategy into execution plans and timelines; Establish governance processes and decision frameworks; Partner with CMC on supply chain readiness; Drive program-level trade-offs and recommendations for the Leadership Team and Board; Manage program-level risk, dependencies, and critical path; Represent the asset in business development assessments and diligence activities.
Seniority
Executive, hands-on IC with strategic oversight